GDP方案治疗复发难治外周T细胞淋巴瘤临床观察

Research on the effect of GDP as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma

目的:观察GDP方案治疗19例复发难治外周T细胞淋巴瘤的客观缓解率、不良反应。方法:19例复发外周T细胞淋巴瘤患者采用GDP方案治疗3周期,观察客观缓解率、主要不良反应。结果:19例患者CR 1例,PR 8例。RR 47.3%。获得缓解的9例患者,复发型8例,难治型1例。获得缓解的IPI低中危组3例,高中危组5例,高危组1例。低中危组与高危组组间差异显著(P<0.05)。主要不良反应是骨髓功能抑制,其中III至IV度为4例(21.1%)。III至IV度胃肠道反应为2例(10.5%)。结论:GDP方案治疗复发外周T细胞淋巴瘤近期疗效确切,安全可行。

Objective：To evaluate efficacy and adverse events of GDP as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma.Methods： Nineteen patients with relapsed or refractory peripheral T cell lymphoma were treated with GDP regimen of 3 cycles.Results： Of the 19 patients,the overall response rate was 47.3%.Of the nine patients with RR,International Prognostic Index（IPI） was 2 in 3 patients.IPI was 3 in 5 patients,IPI was 4-5 in one patient.The major toxicity was myelosuppression.Incidences of neutropenia and thrombocytopenia of grade III-IV were 21.1%.Incidence of nausea and vomit of grade I-II was 78.9%.Conclusion： regimen of GDP is an effective and tolerable regimen for relapsed or refractory peripheral T cell lymphoma.